| Autor: |
Kasper S; West German Cancer Centre, University Hospital Essen, University of Duisburg-Essen, Germany. Electronic address: stefan.kasper@uk-essen.de., Foch C; Merck Healthcare KGaA, Darmstadt, Germany., Esser R; Merck Healthcare KGaA, Darmstadt, Germany., Lamy FX; Merck Healthcare KGaA, Darmstadt, Germany., Zhang A; Merck Serono (Beijing) Pharmaceutical R&D Co., Ltd, Beijing, China., Cheng AL; National Taiwan University Cancer Center, Taipei, Taiwan., Rouyer M; Bordeaux PharmacoEpi, INSERM CIC1401, University of Bordeaux, Bordeaux, France., Brodowicz T; Internal Medicine, Vienna General Hospital and Medical University of Vienna, Austria., Zielinski C; Comprehensive Cancer Centre, Vienna General Hospital and Medical University of Vienna, Austria. |
| Abstrakt: |
Competing Interests: Conflict of interest statement The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: S. Kasper discloses honoraria (self) from Merck, Amgen, Roche, Sanofi, Aventis, Servier, BMS, MSD, Pierre Fabre and Lilly; honoraria (institution) from Merck, BMS, Amgen, Roche, and Lilly; advisory/consultancy roles with Merck, Amgen, Roche, Sanofi, Aventis, Servier, BMS, MSD, Novartis, Pierre Fabre and Lilly; research grants/funding (self) from Merck, Roche, BMS and Lilly; research grants/funding (institution) from Merck, Roche, BMS and Lilly; travel/accommodation expenses from Merck, Amgen, Roche, Sanofi, Aventis, Servier, and Lilly. C. Foch is a full-time employee of Merck Healthcare KGaA, Darmstadt, Germany. R. Esser was a full-time employee of Merck Healthcare KGaA, Darmstadt, Germany, during the work that is the subject of this letter and holds shares of Merck KGaA. F-X Lamy was a full-time employee of Merck Healthcare KGaA, Darmstadt, Germany during the work that is the subject of this letter. A. Zhang is a full-time employee of Merck Serono Co., Ltd., Beijing, China, an affiliate of Merck KGaA. T. Brodowicz discloses personal fees from Roche (lecture fee), Amgen (lecture fee, advisory board), Bayer (lecture fee, advisory board), Novartis (lecture fee, advisory board), PharmaMar (lecture fee, advisory board), Eisai (lecture fee, advisory board), and Lilly (lecture fee, advisory board), outside the submitted work. C. Zielinski discloses consultancy with Roche, Novartis, BMS, MSD, Imugene, ARIAD, Pfizer, Merrimack, Merck KGaA, FibroGen, AstraZeneca, Tesaro, Gilead, Servier, Shire, Lilly, and Athenex, and speaker's honoraria from Roche, Novartis, BMS, MSD, Imugene, ARIAD, Pfizer, Merrimack, Merck KGaA, FibroGen, AstraZeneca, Tesaro, Gilead, Servier, Shire, Lilly, and Athenex. All remaining authors have nothing to disclose. |
Full Text from ScienceDirect